Zymeworks’ leading-edge ZymeCAD™ protein engineering technology platform has enabled the development of a diverse portfolio of proprietary antibody and antibody alternative products.
Platform Technologies |
|||||||
|---|---|---|---|---|---|---|---|
| Indication | Partnering | In silico | In vitro | Ex vivo | In vivo | Clinical | |
| Azymetric™ Scaffold | Multiple |  |
|||||
| EFECT™ Platform | Oncology, Autoimmune | Active Discussions | |||||
| Serum Half-life | Multiple | ||||||
| AlbuCORE™ Scaffold | Multiple | ||||||
Therapeutics Pipeline |
|||||||
| Program 1 | Autoimmune | ||||||
| Program 2 | Not Disclosed | ||||||